Human medicines European public assessment report (EPAR): Glivec, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Gastrointestinal Stromal Tumors,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 07/11/2001, Revision: 35, Status: Authorised

2019 ◽  
Author(s):  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Lymphoblastic Leukemia ◽  
Hypereosinophilic Syndrome ◽  
Precursor Cell ◽  
Assessment Report ◽  
Stromal Tumors ◽  
European Public ◽  
Myeloproliferative Diseases ◽  
European Public Assessment Report
Sign in / Sign up

Export Citation Format

Share Document